Company insight


Diagnostics for vaccine- preventable diseases


Laboratory tests for vaccine-preventable diseases support diagnosis of acute cases and determination of individual immune status. EUROIMMUN offers an extensive portfolio of serological tests for detection of IgG and IgM antibodies against different pathogens, together with PCR-based assays for direct detection of selected parameters.


ome vaccine-preventable diseases (VPD) are resurging due to stagnating or declining rates of vaccination and insufficient population immunity. Of particular concern are highly contagious diseases such as measles and whooping cough, which cause significant morbidity and mortality in children. Laboratory tests play an important role in acute diagnostics, immune status determination and epidemiological surveillance. Acute laboratory diagnostics are generally based on PCR-based direct pathogen detection and serological detection of IgM antibodies and/or a significant titre increase in IgG antibodies. The presence of pathogen-specific IgG antibodies in cerebrospinal fluid can support diagnosis of acute central nervous system infections such as meningitis or encephalitis. To determine an individual’s immune status, the specific IgG concentration in serum is quantified in relation to international reference material. If no reference material exists, for example for mumps virus, the assay can help to assess previous exposure to the pathogen or vaccine. EUROIMMUN (part of Revvity) offers an extensive range of ELISAs and chemiluminescence immunoassays (ChLIAs) for determination of IgG and IgM antibodies against different agents of VPD. These are complemented by selected real-time PCR assays for direct pathogen detection. All analyses can be fully automated using state-of-the-art instrumentation and software for increased efficiency and standardisation.


S EUROIMMUN assays provide sensitive and specific detection of antibodies against various VPD pathogens.


application. For example, use of recombinant proteins for detection of IgM against measles, rubella and varicella zoster virus (VZV) ensures high specificity. For detection of IgG antibodies, viral lysates provide high sensitivity. Inclusion of antigens from vaccination strains, for example for mumps virus, helps to boost the serological detection rate in vaccinated individuals.


Assays for detection of antibodies


against Bordetella pertussis are based on specific pertussis toxin (PT), which enables exclusion of B. parapertussis infection. For tetanus and diphtheria, assays based on toxoids from the respective bacteria enable determination of the immune status and vaccination control.


Dried blood spots Optimal antigens


The antigen preparations used in EUROIMMUN immunoassays are designed for optimal performance in each


Practical Patient Care / www.practical-patient-care.com


The newly launched EUROIMMUN Anti- Measles Virus ELISA 2.0 (IgG) offers the option of using either dried blood spots (DBS) or venous blood as starting material. With DBS only a small blood volume is required, and logistical aspects such as sample collection, storage and transport


are simplified. At the diagnostic laboratory, the DBS can be punched out and analysed using automated systems. Further ELISAs for use with DBS are in development.


Direct detection EUROIMMUN’s serology offerings are complemented by real-time PCR assays for direct detection of selected pathogens. A EURORealTime assay for detection of respiratory syncytial virus (RSV) including differentiation of the viral types A and B has recently been introduced. Vaccination or immunisation to RSV is now recommended in many countries for older persons, pregnant women and infants. Also offered are PCR kits manufactured by GeneProof (part of NuvinkaDx), for example, for detection of VZV or for detection and differentiation of B. pertussis and B. parapertussis in a single reaction. ● Regulatory status, precise intended use and product availability must be verified for the user’s individual jurisdiction.


www.euroimmun.com 15


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45